PHARMACOVIGILANCE IN CLINICAL RESEARCH: PAST, PRESENT AND FUTURE
Journal Title: International Journal of Drug Regulatory Affairs - Year 2016, Vol 4, Issue 4
Abstract
The growing clinical research after the product patents rights for the pharmaceutical industries as per the trade related aspects of intellectual property rights agreement and adverse drug reaction monitoring of the marketed drugs have raised many ethical and regulatory issues regarding the promotion of new drugs in Indian markets. It becomes vital to understand the history, growth and evolution of the regulatory aspects of drugs which are handled by multiple Ministries and Departments of the Government of India. Although amendment to Schedule Y, registration of Ethics committee, registration of Clinical Trials, Speeding up review process, Pharmacovigilance (PhV) programme for India and Inspection of clinical trial sites have been started by the various regulatory agencies. India’s growing partaking in multinational trials, this artifact explores potential areas of Indian pharmacovigilance, requiring reform and provides recommendations for building a robust safety reporting system. (1) Despite global focus on Development Safety Update Report, local regulators are not yet insistent on real-time update of a drug's cumulative safety profile. Issues like reporting requirements for generic trials, pregnancy reporting and lenient timeline for death/life-threatening events need attention. (2)
Authors and Affiliations
Chauhan Pratibha, Yadav Ashish, Kirodian Babita
Keywords
Related Articles
- EP ID EP337075
- DOI 10.22270/ijdra.v4i4.188
- Views 127
- Downloads 0
GERMANY PATENT SYSTEM – AN OVERVIEW
Patent is one of the intellectual property rights, by which the innovator gets exclusive rights or legal monopoly grated to an individual or a firm to make use or sell or reproduce and excluding others from doing so. The...
Regulatory requirements for Drug master file in context to Canada and Australia
Drug Master Files are required in most countries as supporting documents for the registration of drug products. DMFs generally contain information pertaining to the chemistry, manufacturing and controls (CMC) sections of...
SYNTHESIS AND CHARACTERIZATION OF A NOVEL BONE GRAFT MATERIAL CONTAINING BIPHASIC CALCIUM PHOSPHATE AND CHITOSAN FORTIFIED WITH ALOE VERA
The bone grafts were prepared using nanohydroxyapatite (nanoHAP) with the extracts of AV and mixed with beta tricalcium phosphate (βTCP) in a ratio of 60:40. The formed BCP was then conjugated with CH to form the bone gr...
BIOBETTERS: THE BETTER BIOLOGICS AND THEIR REGULATORY OVERVIEW
The continuous innovation of the biopharmaceutical industry has led to development of a new category of biopharmaceuticals i.e. Biobetters or Biosuperiors. Biobetters may have better efficacy, a longer half-life, lower d...
Overview of current Regulations governing Medical Devices
Medical Device (MD) is one of the fastest growing sector and so are the associated regulations. From lack of even policies and guidelines to stringent MD legislations in others, the requirements vary across countries. Un...